Lipella Pharmaceuticals (LIPO) News Today $0.72 +0.02 (+2.71%) As of 02:30 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period LIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 26, 2025 | finanznachrichten.deLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 25, 2025 | globenewswire.comNasdaq delists Lipella Pharmaceuticals over rule violationsJune 22, 2025 | investing.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 21, 2025 | finanznachrichten.deLipella stock tumbles after Nasdaq delisting over rule violationsJune 20, 2025 | in.investing.comLipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 20, 2025 | globenewswire.comLipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic TechnologyJune 17, 2025 | globenewswire.comLipella Pharmaceuticals extends manufacturing pact with Cook MyoSiteJune 5, 2025 | investing.comLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | globenewswire.comLipella Pharmaceuticals to appeal Nasdaq noncompliance warningMay 20, 2025 | bizjournals.comLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | globenewswire.comLipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOMApril 25, 2025 | markets.businessinsider.comLipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025April 23, 2025 | finanznachrichten.deLipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen PlanusApril 23, 2025 | theglobeandmail.comLipella Pharmaceuticals announces results from second cohort of LP-310 trialApril 23, 2025 | markets.businessinsider.comLipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”April 23, 2025 | globenewswire.comLipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen PlanusApril 22, 2025 | reuters.comLipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025April 22, 2025 | globenewswire.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen PlanusApril 8, 2025 | finanznachrichten.deLipella Pharmaceuticals completes enrollment in LP-310 trialApril 8, 2025 | markets.businessinsider.comLipella enrols all subjects in Phase IIa trial targeting oral lichen planusApril 8, 2025 | finance.yahoo.comLipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen PlanusApril 8, 2025 | globenewswire.comLipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastMarch 31, 2025 | globenewswire.comLipella Pharmaceuticals files to sell 5.62M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Announces Key February TransactionsMarch 7, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private PlacementMarch 4, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private PlacementMarch 4, 2025 | globenewswire.comBiotech Rips On Topline AnalysisFebruary 11, 2025 | msn.comLipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trialFebruary 11, 2025 | markets.businessinsider.comLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusFebruary 11, 2025 | globenewswire.comThese 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last WeekFebruary 10, 2025 | msn.comFDA approves Lipella's oral treatment access programFebruary 6, 2025 | msn.comFDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock UpFebruary 6, 2025 | markets.businessinsider.comLipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen PlanusFebruary 6, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private PlacementJanuary 10, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc. ...January 10, 2025 | gurufocus.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | investing.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | globenewswire.comSpartan Capital Securities, LLC Caps Off a Remarkable Year with Key December TransactionsDecember 31, 2024 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private PlacementDecember 18, 2024 | globenewswire.comLipella Pharmaceuticals announces publication in CUREUSDecember 4, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)November 21, 2024 | markets.businessinsider.comLipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose GroupNovember 21, 2024 | globenewswire.comLipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance ChallengesNovember 16, 2024 | markets.businessinsider.comLipella issued patent by USPTO for liposomal drug delivery platformNovember 12, 2024 | markets.businessinsider.comLipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery PlatformNovember 12, 2024 | globenewswire.comLipella Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNovember 1, 2024 | globenewswire.com Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address LIPO Media Mentions By Week LIPO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIPO News Sentiment▼0.590.63▲Average Medical News Sentiment LIPO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIPO Articles This Week▼11▲LIPO Articles Average Week Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXMD News Today CSCI News Today ABP News Today TRIB News Today SNPX News Today GOVX News Today BCDA News Today ATNF News Today IMCC News Today IBIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIPO) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
